Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.70
- Piotroski Score 2.00
- Grade Buy
- Symbol (EVO)
- Company Evotec SE
- Price $3.65
- Changes Percentage (2.24%)
- Change $0.08
- Day Low $3.58
- Day High $3.66
- Year High $12.00
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 01/11/2019
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.28
- Trailing P/E Ratio -17.07
- Forward P/E Ratio -17.07
- P/E Growth -17.07
- Net Income $-83,913,000
Income Statement
Quarterly
Annual
Latest News of EVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
3 Top Stocks to Buy to Cash In on the AI-Fueled Digital Revolution
AI drives demand for data centers and energy, benefiting companies like Brookfield Infrastructure, Equinix, and Kinder Morgan. These firms are well-positioned to profit from the growth in digital infr...
By Yahoo! Finance | 19 hours ago -
The Consumer Revolution In Medicine Is (Finally) Here: What Comes Next?
Patients are increasingly seeking convenience in healthcare through telemedicine, online appointments, and AI tools. Advances like at-home diagnostics and generative AI are reshaping the doctor-patien...
By Forbes | 19 hours ago -
Labor threatens visa cancellations after protests; Baby Reindeer wrongly billed as 'true story'; and a scrappy punk band's evolution
Sign up for the Afternoon Update and Morning Mail newsletters to receive daily updates. The Australian government warns against inciting discord and supporting terrorist organizations, threatening to ...
By The Guardian | 21 hours ago
